Skip to main content

Table 1 Patients’ characteristics of the HPBC and HNBC cohorts, and comparison of clinicopathological features of breast tumors in low and high tATM group

From: Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer

Baseline characteristics HNBC cohort HPBC cohort
Full cohort tATM low tATM high tATM low vs high Full cohort tATM low tATM high tATM low vs high
n = 168 (%) n = 22 (%) n = 79 (%) P value n = 130 (%) n = 36 (%) n = 66 (%) P value
Age median (min-max) 53 (30–82) 58 (33–80) 51(30–82) 0.145 67 (38–88) 71(41–86) 68 (38–88) 0.408
Tumor size         
T1/T2 (≤5 cm) 143 (85%) 20 (20%) 67 (66%) 1.00 116 (89%) 27 (26%) 65 (64%) 0.002
T3/T4 (>5 cm) 16 (10%) 2 (2%) 10 (10%)   10 (8%) 7 (7%) 1 (1%)  
Missing 9 (5%)   2 (2%)   4 (3%) 2 (2%)   
Grade         
1 3 (2%) 0 (0%) 0 (0%) 0.295 25 (19%) 6 (6%) 12 (12%) 0.029
2 29 (17%) 5 (5%) 9 (9%)   63 (48%) 10 (10%) 38 (37%)  
3 121 (72%) 17 (17%) 68 (67%)   32 (25%) 15(14.5%) 15(14.5%)  
Missing 15 (9%)   2 (2%)   10 (8%) 5 (5%) 1 (1%)  
LVI         
+ 47 (28%) 7 (7%) 27 (27%) 0.621 26 (20%) 7 (7%) 13 (13%) 0.584
- 97 (58%) 15(15%) 43 (42%)   76 (58%) 17 (16%) 43 (42%)  
Missing 24 (14%)   9 (9%)   28 (22%) 12 (12%) 10 (10%)  
LN         
0 97 (58%) 15(15%) 41 (40%) 0.230 67 (51%) 14 (14%) 38 (37%) 0.03
>0 64 (38%) 7 (7%) 37 (37%)   49 (38%) 20 (19.5%) 20 (19.5%)  
Missing 7 (4%)   1 (1%)   14 (11%) 2 (2%) 8 (8%)  
Stage         
I 55 (33%) 4 (4%) 25 (25%) 0.551 40 (31%) 6 (6%) 25 (24%) 0.002
II 81 (48%) 13 (13%) 35 (34%)   43 (33%) 13 (13%) 22 (21.5%)  
III 23 (14%) 4 (4%) 16 (16%)   25 (19%) 15 (14.5%) 7 (7%)  
DCIS and IV 9 (5%) 1 (1%) 3 (3%)   3 (2%) 0 (0%) 1 (1%)  
Missing NA     19 (15%) 2 (2%) 11 (11%)  
ER/PR status         
Positive 11 (7%) 0 (0%) 0 (0%)   130 (100%) 36 (35%) 66 (65%)  
Negative 48 (92%) 22 (22%) 79 (78%)   NA    
Missing 2 (1%)     NA    
HER2 status      NA    
Positive 62 (36%) 6 (6%) 33 (33%) 0.22     
Negative 104 (62%) 16 (16%) 46 (45%)      
Missing 2 (1%)        
RT         
Yes 100 (60%) 11 (11%) 55 (54%) 0.127 70 (54%) 20 (20%) 38 (37%) 0.831
No 68 (40%) 11 (11%) 24 (24%)   56 (43%) 15 (15%) 25 (24%)  
Unknown NA     4 (3%) 1 (1%) 3 (3%)  
Chemotherapy         
Anthracycline-based 105 (62%) 11 (11%) 59 (58%) 0.04     
Anthracycline and taxane-based 11 (7%) 3 (3%) 3 (3%)      
CMF or 5FU 7 (4%) 0 (0%) 4 (4%)      
Unknown 3 (2%) 1 (1%) 1 (1%)   1 (1%)    
None 42 (25%) 7 (7%) 12 (12%)   129 (99%)    
  1. One hundred and sixty-eight HNBC and 130 HPBC patients diagnosed with EBC were included in the study. Clinical and histopathological features were summarized and described in numeric numbers and proportions in both cohorts. Sixty-seven cases in the HNBC cohort and 28 cases in the HPBC cohort were excluded for failing to obtain ATM staining due to technical issues. Therefore, a total of 101 cases in the HNBC cohort and 102 cases in the HPBC cohort were dichotomized into high and low ATM groups based on tATM AQUA scores. The cut-point was set at 22% in the HNBC cohort and 38% in the HPBC cohort respectively based on X-tile prediction. Student’s t test was used to compare the continuous variable age between low and high ATM groups. Fisher’s exact test was used to compare the clinicopathological features of breast tumors in high and low ATM groups. HPBC, hormone-positive breast cancer; HNBC, hormone-negative breast cancer; tATM, tumor ATM; LVI, lymphvascular invasion; LN, lymph node status; DCIS, ductal carcinoma in situ; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; RT, radiation treatment; CMT, combined modality treatment; 5FU, 5-fluorouracil; EBC, early-stage breast cancer; ATM, ataxia telangiectasia mutated; AQUA, automated quantitative immunofluorescence analysis.